Company: Somaxon Pharmaceuticals Inc, SOMX
Price: 5.13
Change: 51.63%
Volume: 19.1M
Procter & Gamble sales representatives will work to promote a new treatment for insomnia through an agreement with San Diego-based Somaxon Pharmaceuticals Inc. The drug, Silenor, is a low-dose oral tablet taken within 30 minutes of bedtime. It is prescribed for insomnia that is characterized by difficulty with staying asleep.
According to the co-promotion deal for Silenor, P&G reps will target primary care doctors and physicians who write a high number of prescriptions for insomnia medication. Somaxon (Nasdaq: SOMX) reps will focus on specialists who treat insomnia. Working together, the companies will have about 215 sales employees targeting Silenor to 35,000 doctors and 25,000 pharmacies in the U.S., according to a press release.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Its principal product Silenor (doxepin) has been approved by the United States Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Solana Beach, California.
The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
No comments:
Post a Comment